EZETIMIBE; SIMVASTATIN | A200909 | DR REDDYS LABORATORIES SA
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
SCHERING CORPORATION et al v. TEVA PHARMACEUTICALS USA, INC.. et al 2 patentsANDA 200909ezetimibe/simvastatin | D.N.J. | 2010-03-02 | Terminated 2011-01-18 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.4524
per ea
Lowest NADAC/Unit
$0.3013
per ea
Brand NDCs
0
Generic NDCs
12
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 43598074590EZETIMIBE-SIMVASTATIN 10-80 MG | $0.4524 | EA | Generic | — | 2026-06-17 |
| 43598074530EZETIMIBE-SIMVASTATIN 10-80 MG | $0.4524 | EA | Generic | — | 2026-06-17 |
| 43598074505EZETIMIBE-SIMVASTATIN 10-80 MG | $0.4524 | EA | Generic | — | 2026-06-17 |
| 43598074210EZETIMIBE-SIMVASTATIN 10-10 MG | $0.3810 | EA | Generic | — | 2026-06-17 |
| 43598074230EZETIMIBE-SIMVASTATIN 10-10 MG | $0.3810 | EA | Generic | — | 2026-06-17 |
| 43598074290EZETIMIBE-SIMVASTATIN 10-10 MG | $0.3810 | EA | Generic | — | 2026-06-17 |
Showing 6 of 12 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.